|
| 36367837 | Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. | Neuro Oncol | 2023 |
| 36367837 | Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. | Neuro Oncol | 2023 |
| 37467106 | High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. | Cell Rep | 2023 |
| 37141550 | A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. | JCO Precis Oncol | 2023 |
| 36638200 | Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations. | Clin Cancer Res | 2023 |
| 37260393 | A genomic score to predict local control among patients with brain metastases managed with radiation. | Neuro Oncol | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 37364233 | Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. | JCO Precis Oncol | 2023 |
| 36791345 | Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 37141550 | A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. | JCO Precis Oncol | 2023 |
| 37467106 | High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. | Cell Rep | 2023 |
| 37364233 | Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. | JCO Precis Oncol | 2023 |
| 37260393 | A genomic score to predict local control among patients with brain metastases managed with radiation. | Neuro Oncol | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36638200 | Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations. | Clin Cancer Res | 2023 |
| 36791345 | Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 35078818 | Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. | Cancer Res | 2022 |
| 36177448 | A patient-driven clinicogenomic partnership for metastatic prostate cancer. | Cell Genom | 2022 |
| 35755401 | A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. | JAMA Health Forum | 2022 |
| 35797509 | Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. | JCO Precis Oncol | 2022 |
| 35078818 | Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. | Cancer Res | 2022 |
| 35101884 | Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. | Clin Cancer Res | 2022 |
| 35797509 | Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. | JCO Precis Oncol | 2022 |
| 35755401 | A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. | JAMA Health Forum | 2022 |
| 36177448 | A patient-driven clinicogenomic partnership for metastatic prostate cancer. | Cell Genom | 2022 |
| 35101884 | Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. | Clin Cancer Res | 2022 |
| 33293374 | Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. | Clin Cancer Res | 2021 |
| 33509999 | Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. | Science | 2021 |
| 34257082 | Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations. | Cancer Res | 2021 |
| 33761455 | Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. | J Natl Compr Canc Netw | 2021 |
| 34302589 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. | Breast Cancer Res Treat | 2021 |
| 33495604 | Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. | Nat Med | 2021 |
| 33293374 | Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. | Clin Cancer Res | 2021 |
| 34952565 | cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. | BMC Bioinformatics | 2021 |
| 34359829 | ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. | Cells | 2021 |
| 33761455 | Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. | J Natl Compr Canc Netw | 2021 |
| 33509999 | Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. | Science | 2021 |
| 33495604 | Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. | Nat Med | 2021 |
| 34952565 | cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. | BMC Bioinformatics | 2021 |
| 34302589 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. | Breast Cancer Res Treat | 2021 |
| 34359829 | ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. | Cells | 2021 |
| 34257082 | Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations. | Cancer Res | 2021 |
| 32404308 | The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. | Cancer Discov | 2020 |
| 32312893 | Identification of a RAS-activating <i>TMEM87A-RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. | Clin Cancer Res | 2020 |
| 32404308 | The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. | Cancer Discov | 2020 |
| 32170028 | Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. | Clin Cancer Res | 2020 |
| 32042194 | The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. | Nat Med | 2020 |
| 32853681 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. | Ann Oncol | 2020 |
| 32723837 | Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 32042194 | The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. | Nat Med | 2020 |